<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03648073</url>
  </required_header>
  <id_info>
    <org_study_id>R18-107</org_study_id>
    <nct_id>NCT03648073</nct_id>
  </id_info>
  <brief_title>[68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma</brief_title>
  <official_title>[68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma to Assess the Feasibility of Targeted Radionuclide Therapy With Somatostatin Receptor Ligands</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is great need for new therapeutic options for patients with hepatocellular carcinoma
      (HCC). This proposal will assess the feasibility of a novel theranostic approach to HCC using
      [68Ga]DOTATATE, a recently approved positron emission tomography (PET) ligand for imaging
      somatostatin receptor (SSTR) positive tumors. In this study, we will use [68Ga]DOTATATE to
      determine the percentage of HCCs that express adequate levels of SSTR for treatment with
      targeted radionuclide therapy (TRT) using the therapeutic SSTR ligand [177Lu]DOTATATE. This
      radionuclide therapy was FDA approved in January 2018 for treating neuroendocrine tumors
      (NETs) arising from the gastrointestinal tract, but its use in HCC has not yet been explored.
      In the long term, we envision using [68Ga]DOTATATE-PET to identify HCC patients with adequate
      SSTR expression for TRT using [177Lu]DOTATATE.

      Liver transplantation is the only curative therapy for HCC and is an option for a selected
      subset of HCC patients. For those who are not candidates for transplantation, locoregional
      therapies with limited efficacy are available such as percutaneous ablation, arterial
      chemoembolization, and Y-90 microsphere radionuclide therapies. There are few options for
      patients who progress or are not candidates for these therapies. The first line systemic
      therapy is sorafenib, a tyrosine kinase inhibitor. Sorafenib is often not well tolerated due
      to its side effects and there is need for additional systemic treatments. Multiple
      tissue-based studies demonstrate SSTR positivity in 20-50% of HCCs.[1-3] However, the
      fraction of HCCs have high enough levels of SSTR for [177Lu]DOTATATE therapy has not yet been
      assessed. This research plan is a critical prerequisite for determining the feasibility of
      this theranostic approach to treating HCC. If we obtain positive results, these data will be
      critical for designing a combined imaging and therapeutic study in HCC using DOTATATE.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 30, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients demonstrating somatostatin receptor positivity in hepatocellular carcinoma using [68Ga]DOTATATE-PET</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Untreated HCC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Previously treated HCC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>[68Ga]DOTATATE-PET/MRI</intervention_name>
    <description>[68Ga]DOTATATE-PET/MRI</description>
    <arm_group_label>Previously treated HCC</arm_group_label>
    <arm_group_label>Untreated HCC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Known diagnosis of hepatocellular carcinoma, either by imaging criteria or pathology
             on biopsy

          -  Standard of care liver MRI or CT demonstrating viable HCC based on arterial contrast
             enhancement measuring at least 1.5 cm in largest axial dimension

        Exclusion Criteria:

          -  History of neuroendocrine tumor or other SSTR-positive tumor

          -  Interval locoregional therapy or new systemic therapy between standard of care liver
             MRI or CT study showing viable HCC and [68Ga]DOTATATE-PET/MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel Galgano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>April L Riddle, RT</last_name>
    <phone>205-966-3435</phone>
    <email>ariddle@uabmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marianne Vetrano, RN</last_name>
    <phone>205-934-4080</phone>
    <email>mvetrano@uabmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Medical Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan McConathy, MD</last_name>
      <phone>205-996-7115</phone>
      <email>jmcconathy@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan McConathy, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bag Asim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bhambhvani Pradeep, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Choudhary Gagandeep, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Geldmacher David, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lapi Suzanne, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffers Charlotte Denise, RPh</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Natelson Marissa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roberson Erik, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 22, 2018</study_first_submitted>
  <study_first_submitted_qc>August 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2018</study_first_posted>
  <last_update_submitted>March 20, 2020</last_update_submitted>
  <last_update_submitted_qc>March 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Samuel Joseph Galgano</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

